XCUR Stock Risk & Deep Value Analysis
Exicure Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About XCUR Stock
We analyzed Exicure Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran XCUR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
XCUR Risk Analysis & Red Flags
What Could Go Wrong
Exicure's current cash balance of approximately $2.5 million as of March 31, 2026, is being rapidly depleted by ongoing operational losses, with Q1 2026 showing a preliminary net loss of ~$1.8 million. If this burn rate continues without a significant capital injection or a successful reverse merger, the company faces insolvency or bankruptcy within 1-2 quarters, leading to a near-total loss for shareholders.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Zero active operations or revenue streams since liquidation of prior assets.
- ⚠
Critically low and declining cash balance of ~$2.5 million as of March 31, 2026, representing a decrease of ~$1.2 million from December 31, 2025.
- ⚠
Preliminary Q1 2026 net loss of ~$1.8 million, indicating ongoing cash burn without any corresponding revenue.
- ⚠
Filed Form 12b-25 on May 15, 2026, delaying the Q1 2026 10-Q filing, indicating regulatory non-compliance and potential delisting risk.
- ⚠
Market cap of $0.02 billion is 8 times its cash balance despite having no business operations or future prospects.
Upcoming Risk Events
- 📅
Failure to file Q1 2026 Form 10-Q within grace period (est. by May 20, 2026): Likely triggers further NASDAQ delinquency notices and potential delisting.
- 📅
Cash balance falls below $1,000,000 by Q3 2026: With a Q1 2026 preliminary net loss of ~$1.8M and cash of ~$2.5M, continued burn threatens insolvency within two quarters without new funding.
- 📅
No reverse merger agreement announced by Q4 2026: Leaves the company as a dormant shell, likely leading to further liquidation or bankruptcy procedures.
When to Reconsider
- 🚪
Exit if Q1 2026 Form 10-Q is not filed by end of May 2026, triggering further NASDAQ delisting warnings.
- 🚪
Sell if cash and cash equivalents fall below $1 million (indicating imminent insolvency without new funding).
- 🚪
Exit if no announcement of a definitive reverse merger agreement is made by the end of Q3 2026.
Unlock XCUR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Exicure Inc (XCUR) Do?
Market Cap
$17.31M
Sector
Healthcare
Industry
Biotechnology
Employees
7
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Visit Exicure Inc WebsiteInvestment Thesis
If Exicure Inc. (XCUR), leveraging its ~$2.5M cash and NASDAQ listing, can attract a high-growth private company for a reverse merger transaction by Q4 2026, then the combined entity could be re-rated significantly above XCUR's current ~$0.02B market cap. This is bullish because the market currently values XCUR as a dormant shell, completely ignoring any potential for a successful strategic transaction to introduce a viable, high-growth business.
Is XCUR Stock Undervalued?
Unlock the full AI analysis for XCUR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
XCUR Price Targets & Strategy
12-Month Target
$0.05
Bull Case
$5.00
Bear Case
$0.01
Valuation Basis
Base target reflects near-liquidation value given continued cash burn and no operations; upside requires a highly speculative reverse merger at a premium to current market cap; downside is complete loss of value upon insolvency or delisting.
Entry Strategy
Avoid investment unless a definitive, high-value reverse merger agreement with a credible operating company is announced.
Exit Strategy
Exit immediately if no definitive reverse merger by Q3 2026 or if cash falls below $1M. Take profits on any reverse merger news above $5.00.
Portfolio Allocation
0% for any risk tolerance; this is purely speculative 'lottery ticket' money if pursued at all.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is XCUR Financially Healthy?
Valuation
P/E Ratio
-3.65
Forward P/E
4.45
EV/EBITDA
4.45
PEG Ratio
-0.01
Price/Book
4.53
Profitability
Operating Margin
-167.20%
Net Margin
-165.80%
Return on Equity
-63.62%
EPS
$-0.77
Balance Sheet
Current Ratio
1.19
Quick Ratio
1.04
Cash & Equivalents
$2.50M
Other
Beta (Volatility)
3.69
Does XCUR Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Exicure Inc. currently possesses no economic moat. Its prior intellectual property and clinical programs in nucleic acid therapies have been liquidated, leaving the company with no active operations, products, or services to build or defend a competitive advantage.
Moat Erosion Risks
- •Complete erosion of remaining brand recognition (from prior biotech work) due to dormancy.
- •Inability to attract or develop new, defensible intellectual property or business lines due to lack of capital and operational focus.
XCUR Competitive Moat Analysis
Sign up to see competitive advantages
XCUR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (due to lack of operations, cash burn, and delisting risk, likely very little retail interest).
Institutional Sentiment
Negative (no analyst coverage, no institutional buying data, indicative of a company without a viable business).
Insider Activity (Form 4)
No specific Form 4 insider transactions (buy/sell) were found in the provided research for the last 90 days. The CEO is Andy Yoo.
Options Flow
Normal options activity (likely very low volume, reflecting lack of interest and certainty).
Earnings Intelligence
Next Earnings
Q1 2026, delayed from May 22, 2026. Expected to be filed within the 5-day grace period from May 15, 2026.
Surprise Probability
Low (The previous 'beat' was a statistical anomaly given the company's lack of operations; expectations for Q1 2026 are likely near current reported preliminary figures of $0 revenue and ~$1.8M net loss).
Historical Earnings Pattern
Not applicable due to the company's dormant status and lack of consistent operational results.
Key Metrics to Watch
Competitive Position
Top Competitor
None (Exicure has no active operations to compare against peers).
Market Share Trend
Losing (no active market share to begin with; previous therapeutic focus has been liquidated).
Valuation vs Peers
Not comparable (no revenue, no earnings, making traditional valuation metrics meaningless against operating companies).
Competitive Advantages
- •None (no active business to create or sustain advantages).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive XCUR Stock Higher?
Near-Term (0-6 months)
- •Filing of Q1 2026 Form 10-Q (est. by May 20, 2026, per 12b-25 grace period): Required to avoid potential NASDAQ delisting; no financial upside unless paired with strategic news.
- •Announcement of a definitive reverse merger agreement (TBD Q2-Q4 2026): Only speculative catalyst; specific target company and deal terms would drive any re-rating.
Medium-Term (6-18 months)
- •Completion of a reverse merger transaction (TBD Q1-Q2 2027): If successful, would introduce new operations, revenue, and assets; requires a substantial influx of new business to justify a 10x valuation.
- •New equity financing post-merger (TBD Q1-Q2 2027): Essential for any new operating entity to fund growth, potentially dilutive to current shareholders but necessary for business viability.
Long-Term (18+ months)
- •Establishment of a new, viable business model (18+ months, dependent on merger): If a reverse merger brings in a high-growth company, it *could* then build revenue streams and intellectual property.
- •Achieving sustainable profitability and positive free cash flow (2-3+ years post-merger): If the new entity can demonstrate this, it would attract institutional capital.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for XCUR?
- ✓
Watch for any 8-K filing announcing a Letter of Intent or Definitive Agreement for a reverse merger, which would be the primary re-rating event.
- ✓
Monitor the cash balance; a failure to stem the cash burn from ~$1.8M/quarter suggests short runway for any strategic pivot.
Bull Case Analysis
Sign up free to see the bull case
Competing with XCUR
See how Exicure Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Exicure Inc XCUR | $17.3M | 0.1 | -3.6 | — | -165.8% | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Exicure Inc Makes Money
Exicure Inc. currently operates as a dormant public shell company. It has no active revenue-generating operations, products, or services. Its prior focus on developing nucleic acid therapies was ceased, and all related assets were liquidated. The company's primary 'business' function is currently to maintain its public listing status, utilizing its remaining cash reserves. Its future, if any, is entirely dependent on a potential reverse merger with an operational private company seeking public market access.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Exicure Inc (XCUR)?
As of May 24, 2026, Exicure Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Exicure Inc?
Exicure Inc's market capitalization is approximately $17.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Exicure Inc use?
XCUR is the ticker symbol for Exicure Inc. The company trades on the NCM.
What is the risk level for XCUR stock?
Our analysis rates Exicure Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of XCUR?
Exicure Inc currently has a price-to-earnings (P/E) ratio of -3.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is XCUR stock profitable?
Exicure Inc has a profit margin of -165.8%. The company is currently unprofitable.
How often is the XCUR DVR analysis updated?
Our AI-powered analysis of Exicure Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for XCUR (Exicure Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.